Basic Searches
Searches without any special characters (listed below) will return items that contain the exact value(s) entered in the search field. This means that searching for "ASPIRIN CALCIUM" won't return any items that have "ASPIRIN GLYCINE CALCIUM" because the search term doesn't match exactly.
Boolean Operators
OR - searches with terms separated by " OR " will return items that contain any of the terms in the search.
Example: "ASPIRIN" OR "CALCIUM" will return items that have strings like "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because they contain at least one of the terms in the search.

AND - searches with terms separated by " AND " will return items that contain all the terms in the search.
Example: "ASPIRIN" AND "CALCIUM" won't return items that have strings "ASPIRIN GLYCINE" and "GLYCINE CALCIUM" because neither contain both terms, but it will return "ASPIRIN GLYCINE CALCIUM" because it contains both search terms.
version 2.7.1
Substance Class Protein
Protein Type TRANSPORTER
Protein Sub Type Other ABC
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
22ES734693
Record Status Validated
Record Version
Show Definitional References Hide Definitional References
Download
Name Type Language Details Access References
MULTIDRUG RESISTANCE PROTEIN 1
Common Name
English  
PGY1
Common Name
English  
P-GP
Common Name
English  
P-GLYCOPROTEIN 1
Common Name
English  
P-GLYCOPROTEIN
Common Name
English  
MULTIDRUG RESISTANCE PROTEIN 1 (HUMAN)
Common Name
English  
MGC163296
Common Name
English  
MDR1
Common Name
English  
MDR-1
Common Name
English  
GP170
Common Name
English  
CLCS
Common Name
English  
CD243
Common Name
English  
CD-243
Code
English  
ATP-BINDING CASSETTE SUB-FAMILY B MEMBER 1
Common Name
English  
ATP-BINDING CASSETTE B1
Common Name
English  
ABCB1
Common Name
English  
ABC20
Common Name
English  
Classification Tree Code System Code Access References
EC (ENZYME CLASS) EC 3.6.3.44
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
UCSF-FDA TRANSPORTAL ABCB1
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
Code System Code Type Description Access References
CAS
1646537-23-6
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
PRIMARY
FDA UNII
22ES734693
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
PRIMARY
UNIPROT
P08183
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_91
N 1_94
N 1_99
Related Record Type Details Access References
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Regorafenib inhibits Pgp and BCRP in vitro.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
In vitro investigations indicated that indacaterol is a low affinity substrate for the efflux pump P-gp.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 20:35:17 EDT 2021 , Edited by admin on Wed Aug 04 20:35:17 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
WEAK
IN VITRO
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Niraparib is a substrate of P-gp and BCRP in vitro.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
IN VITRO
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Drugs that induce or inhibit CYP3A, P-gp, and BCRP may affect temsavir plasma concentrations.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 05:13:39 EDT 2021 , Edited by admin on Wed Aug 04 05:13:39 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
COADMINSTERED WITH RITONAVIR TO INCREASE BIOAVAILABILITY
Created by admin on Wed Aug 04 08:55:58 EDT 2021 , Edited by admin on Wed Aug 04 08:55:58 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Relugolix is a substrate for intestinal P-gp.Co-administration with rifampin (P-gp and strong CYP3A inducer) decreased the AUC and Cmax of relugolix by 55% and 23%, respectively.
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 04:04:17 EDT 2021 , Edited by admin on Wed Aug 04 04:04:17 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Cabotegravir is a substrate of P-gp and BCRP in vitro; however, because of its high permeability, no alteration in cabotegravir absorption is expected with coadministration of P-gp or BCRP inhibitors.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INDUCER -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 18:36:19 EDT 2021 , Edited by admin on Wed Aug 04 18:36:19 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
WEAK
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
The in vitro study result indicated that alpelisib is a weak P-gp inhibitor with a Ki of 98.6 ?M (R0900459).
Ki
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 04:18:05 EDT 2021 , Edited by admin on Wed Aug 04 04:18:05 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Co-administration of talazoparib with certain P-gp inhibitors including amiodarone, carvedilol, clarithromycin, itraconazole, and verapamil in the clinical studies (PRP-001, PRP-002, ABRAZO and EMBRACA) increased talazoparib exposure by 44.7%, in conjunction with an increased rate of Talzenna dose reductions (41%).
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
MAJOR
a high-fat meal increased bosutinib AUC 1.7-fold and Cmax 1.8-fold compared with bosutinib administration under fasting conditions
Created by admin on Wed Aug 04 08:36:35 EDT 2021 , Edited by admin on Wed Aug 04 08:36:35 EDT 2021
INHIBITOR -> TARGET
none
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
The sponsor evaluated ospemifene as a potential substrate for transporters in a P-gp in vitro study. No in vivo transporter studies were conducted.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
INHIBITOR
IC50
Created by admin on Wed Aug 04 04:18:05 EDT 2021 , Edited by admin on Wed Aug 04 04:18:05 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
WEAK
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Simeprevir inhibited P-gp-dependent transport of paclitaxel in Caco-2 cells with an IC50 value of 64.4 ug/mL (Study NC113).
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
In ABCB1-overexpressing cells, ulixertinib antagonized MDR by attenuating the efflux function of ABCB1. A combination of ulixertinib with anticancer drugs to attenuate MDR mediated by ABCB1 or ABCG2 in cancer cells overexpressing these transporters.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INDUCER -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INDUCER -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
INHIBITOR
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
However, because of low oral bioavailability, inhibition of P-gp is unlikely to have an impact on the overall bioavailability of vilanterol.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 16:06:24 EDT 2021 , Edited by admin on Wed Aug 04 16:06:24 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Abiraterone acetate inhibits Pgp significantly, with an IC50 of 10.8 ?M in vitro.
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Based on in vitro results
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INDUCER -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
In overexpressing BCRP and P-gp cell line, the estimate Km for both transporters is >300 ?M. Coadministration of larotrectinib with a single dose of a P-gp inhibitor (rifampin), increased the AUCinf of larotrectinib by 1.7-fold and the Cmax by 1.8-fold as compared to larotrectinib administered alone.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> METABOLIC ENZYME
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
TRANSPORTER
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
NON-SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 03:10:23 EDT 2021 , Edited by admin on Wed Aug 04 03:10:23 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Lasmiditan is an in-vitro inhibitor of P-gp and BCRP.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
WEAK
clinical studies indicate that voclosporin is a weak inhibitor of P-gp
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
inhibited MTX efflux transport in MDR1-MDCK and MRP2-MDCK cellmonolayers, suggesting that the target of drug interaction wasMDR1 andMRP2 in the intestine duringthe absorption process.
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INDUCER -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Lonafarnib is likely a marginal substrate of P-gp.
Created by admin on Wed Aug 04 01:48:53 EDT 2021 , Edited by admin on Wed Aug 04 01:48:53 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
LDV is a substrate for P-gp and BCRP in vitro (AD-256-2144 and AD-256-2150).
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TARGET
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
IC50
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
WEAK
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
INHIBITOR
Gao et al. reported that in vitro, imatinib (1 M) increases the intracellular concentration of vincristine and mitoxantrone in cells overexpressing ABCB1 and ABCG2, respectively.
CLINICALLY SIGNIFICANT
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:51 EDT 2021 , Edited by admin on Wed Aug 04 01:48:51 EDT 2021
SUBSTRATE -> TRANSPORTER
Mediator Substance Details
none
Crizotinib is a substrate for P-glycoprotein in vitro.
Created by admin on Wed Aug 04 04:12:27 EDT 2021 , Edited by admin on Wed Aug 04 04:12:27 EDT 2021
SUBSTRATE -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
INHIBITOR -> TRANSPORTER
none
Mediator Substance Details
none
Created by admin on Wed Aug 04 01:48:52 EDT 2021 , Edited by admin on Wed Aug 04 01:48:52 EDT 2021
SUBSTRATE -> TRANSPORTER
none